

Dr Kosh Agarwal

BMedSci (Hons) MD FRCP(Ed)

Current appointment: **Consultant Hepatologist/ Transplant Physician**
Institute of Liver Studies, Kings College Hospital

Specialist Interests: **End stage Liver Disease/ Assessment for Transplantation**
Clinical lead for Viral Hepatitis (Hepatitis C and B)
Living Donor Liver Transplantation management
Hepatocellular Carcinoma

I am one of 4 Consultant Hepatologists with an interest in Transplantation at Kings College Hospital. I provide and lead the Viral Hepatitis Service and a 'Key Opinion Leader' in my chosen areas of expertise. I act as a medical advisor to a national charity (Hepatitis C Trust) and acted as an expert for the Westminster All Party Hepatology Group Audit.

The Institute of Liver Studies service is probably the largest comprehensive clinical liver programme in the world. It provides an integrated investigation and treatment service for all types of acute and chronic liver diseases. The research ethos puts considerable emphasis on understanding the pathogenesis of all types of liver disease and on continuing the profile of King's as world-leaders in clinical innovation and patient management. Routine and emergency cases are accepted to the core services of liver transplantation, liver intensive care and general hepatology. The liver transplant programme currently performs 160-190 transplants (approximately 2/3 adult, 1/3 paediatric) annually. Prior to this I was appointed as Consultant Hepatologist/ Senior Lecturer at the Liver Transplant Unit, Newcastle upon Tyne for a period of 22 months.

As part of my training in Hepatology and Transplantation I spent a year at the Mt Sinai Medical Center in New York as an Advanced Hepatology Fellow. I was able to focus on the specific strengths of the Mount Sinai Transplant program. I gained experience in living related liver transplantation, 'difficult to treat' viral hepatitis *i.e* HIV/ Hepatitis C co-infection, pre-transplant Hepatitis C and B (DT Dieterich), Hepatocellular carcinoma (M Schwartz, J Llovet), Wilsons Disease (M Schilsky) and post transplant recurrent Hepatitis C (T Schiano). I participated as a member of the small bowel transplantation team (G Gondolesi) and worked in a 'high volume' liver transplant environment.

My postgraduate training within the Northern Region has provided me with a broad spectrum of generic and sub-specialist skills in Hepatology and Transplantation. During my training, I spent 4 years (including my research period) working on the Regional Liver and Transplant unit. This is a joint medical and surgical unit, with multi-disciplinary support and strong academic links to the University of Newcastle. Specific areas of expertise are alcohol, viral hepatitis and autoimmune liver disease.

I am experienced in the management of acute and chronic liver disease, in particular, those patients with viral hepatitis, hepatocellular carcinoma, end-stage liver disease and those undergoing transplantation. I am experienced in the management of patients with viral hepatitis and co-infection, specifically patients undergoing assessment for treatment, receiving antiviral therapy and the ongoing monitoring of their treatment. I am a competent endoscopist.

Employment History:

May 04 – March 06 Consultant Hepatologist/ Honorary Senior Lecturer
Regional Liver and Transplant Unit,
Freeman Hospital, High Heaton
Newcastle upon Tyne, NE7 7DN

July 03- May 04 Advanced Hepatology Fellowship
Division of Liver Diseases
Mount Sinai Medical Center, 1 Gustave Levy Place
New York, NY

Northern Specialist Registrar Rotation: NTN/018/006N CCST: 01/05/04
Gastroenterology and General Internal Medicine

Awards: BASL travel award 1998, 1999
European Young Investigator travel award (EASL) 1999
Liver and Immunology poster prize Falk Liver Week 1999
AASLD Young Investigator travel award (STC) 1999

Elective: Student Fellowship at Dept Neuroimmunology, Johns Hopkins Medical
Institute, USA (7-10/89)

Professional Associations: American Association for the study of Liver Disease (AASLD)
European Association for the study of the Liver (EASL)
British Association for the study of the Liver (BASL)
Royal College of Physicians (RCP)
British Medical Association (BMA)

Referees: Professor Scott Friedman, Chief, Division of Liver Diseases,
Fishberg Professor of Medicine.
Box 1123, Mount Sinai School of Medicine, 1425 Madison Avenue, Room 1170F,
New York, NY 10029.
Telephone: 212-659-9501, Fax: 212-849-2574
Email: Scott.Friedman@mssm.edu.

Profesor N Heaton, Clinical Head of Transplantation, Consultant Hepatobiliary and
Liver Transplant Surgeon.
Institute of Liver Studies, King College Hospital
Denmark Hill
London.

Publications:

Webber SK, Andrews RA, **Agarwal K**, Gillie RJ, Cotterill DG.
Subretinal pseudomonal abscess following lung transplantation. *Br J Ophthalmol* 1995; 142: 22.

Agarwal K, Jones DEJ and Bassendine MF.
Genetic susceptibility to PBC. *Eur J Gastroenterol & Hepatol* 1999; 11:603-608.

Agarwal K, Jones DEJ. Treatment of Hepatitis C infection. *BMJ* 1999; 319: 450-1.

Agarwal K, Manas DM, Hudson M. Fulminant Hepatic failure related to terbinafine.
N Engl J Med 1999; 340; 1292-3.

Agarwal K, Jones DEJ, Daly AK, Vaidya B, OFW James, SHS Pearce and Bassendine MF.
CTLA-4 gene polymorphism associated with Primary Biliary Cirrhosis.
J Hepatol 2000; 32: 538-541.

Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT.
CTLA-4 polymorphisms and susceptibility to Type 1 Autoimmune Hepatitis (AIH).
Hepatology 2000; 31: 49-53.

Donaldson PT, **Agarwal K**, Craig W, James OFW, Jones DEJ.
Interleukin-1 gene polymorphisms associated with disease progression in primary biliary cirrhosis *Gut* 2001; 48: 397-402.

Jowett SL, **Agarwal K**, Smith BC, Kerrigan J, Hewett M, Bassendine DR, Gilvarry E, Burt AD, Bassendine MF.
Chronic Hepatitis C acquired through intravenous drug use: audit of medical management.
QJM 2001; 94: 153-8.

Pummeechockai W, Bevitt D, **Agarwal K**, Langer B, Petropoulou T, Belohradsky B, Bassendine MF, Toms GL.
Hepatitis C particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients- implications for virus clearance by antibody. *J Med Virol* 2002; 68: 335-42.

Agarwal K, Jones DEJ, Watt FE, Floreani AR, Burt AD, Bassendine MF.
Familial PBC and Autoimmune Cholangitis: *Dig and Liver Diseases* 2002; 34: 50-2.

McRae CA, **Agarwal K**, Mutimer D, Bassendine MF.
Hepatitis associated with Chinese Herbs. *Euro J Gastroenterol & Hepatol* 2002; 14: 1-4.

Agarwal K, Jones DEJ, Burt AD, Hudson M, James OFW.
Metastatic breast carcinoma presenting as acute liver failure and portal hypertension.
Am J Gastrol 2002; 97: 750-1.

Kontorinis N, **Agarwal K**, O'Rourke M, Gondolesi G, Fiel I and Schiano TD.
Diagnosis of 6 Mercaptopurine Hepatotoxicity Post Liver Transplantation Using Metabolite Assays. *American Journal of Transplantation* 2004; 4: 1539-42.

Kontorinis N, **Agarwal K** and Dieterich DT.

Current Status on the Use of Growth Factors and other Adjuvant Medicines in Patients Receiving Peginterferon and Ribavirin. *Reviews in Gastroenterological Disorders* 2004: 4: S39-47.

Agarwal K, Kontorinis N, Dieterich DT. Alcoholic Hepatitis: review.

Curr Treat Options in Gastroenterology 2004: 7: 451-458.

Baragiotta A, Floreani AR, **Agarwal K**, Craggs A, Venturi C, Jones DEJ, Bassendine MF, Donaldson PT.

Chemokine E and PBC: a twin centre genetic association study. *Liver Int* 2004: 24: 646-50.

Dieterich DT, Kontorinis N, **Agarwal K**. Managing Dual Morbidities: HIV/HCV Co-infection in Clinical Practice. *JIPAC* 2004: 3: S4-17.

Kontorinis N, **Agarwal, K** and Dieterich, DT.

Treatment of HCV in HIV patients. *AIDS* 2005: 19: S166-73.

Fenwick F, Bassendine MF, **Agarwal K**, Bevitt D, Pummeechockai W, Burt AD, Toms GL. Immunohistochemical assessment of HCV antigen in cholestatic hepatitis after transplantation.

J Clin Path 2006: 59: 174-8.

Hudson M, **Agarwal K**.

Alcoholism and Alcoholic Liver Disease. Medical care of the Liver Transplant patient, 3rd edition. book chapter: 2006: 139-149.

Tapirdamaz O, Pravica V, Metselaar HJ, Hansen B, Moons L, Arash AK, Van Meurs J, Hutchinson IV, Shaw J, **Agarwal K**, Day CP, Adams DH, Kwekkeboom J.

Polymorphisms in the T-cell regulatory gene CTLA-4 are associated with susceptibility for acute rejection after liver transplantation. *Gut* 2006: 55: 863-8.

Kontorinis N, **Agarwal K**, Elhajj N, Fiel MI, Schiano TD.

Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.

Liver Transplantation 2006: 12: 827-30.

Hayes P, **Agarwal K**, Galiza . Alarm Bells in Medicine: Hepatology book chapter: 2006: 54-58.

Kontorinis N, **Agarwal K**, Dieterich DT.

Management of the patient with hepatitis B and HIV infection.

The Mt Sinai Journal of Medicine (In Press).

Wilson CH, **Agarwal K**, Talbot D, Jacques BC, Manas DM, Carter V, Burt AD, Hubscher S.

Late acute humoral rejection in a compliant ABO compatible liver transplant recipient.

Transplantation 2006: 82: 988-9.

Khapra A, **Agarwal K**, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD.

Impact of donor age on survival and fibrosis progression in patients with HCV undergoing transplantation with HCV+ allografts.

Liver Transplantation 2006: 12: 1496- 503.

Agarwal K, Cross TJS, Gore.C.
Chronic Hepatitis C. Editorial *BMJ* 2007: 334: 54-55.

Browne E, Cressey DM, **Agarwal K**, Cosgrove JF.
The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant.
Anaesthesia 2007: 62: 282-5.

Agarwal K, Czaja AJ, Donaldson PT.
A functional FAS promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterised by early development of cirrhosis.
Tissue Antigens 2007: 69; 227-35

Stanca C, Fiel MI, Kontorinis N, **Agarwal K**, Emre S, Schiano TD.
Chronic ductopenic rejection in patients with recurrent hepatitis c treated with pegylated interferon 2a and ribavirin
Transplantation 2007: 13: 1382-8.

Reddy MS, Smith L, Jacques BC, **Agarwal K**, Hudson M, Talbot D, Manas DM
Do laproscopy and introporative ultrasound have a role in the assessment of patients with end stage liver disease and hepatocellular carcinoma for liver transplantation?
Transplant Proc 2007: 39: 180-6.

Cross TJ, Antoniades CG, Muiesan P, Al-Chalabi T, Aluvihare V, **Agarwal K**, Portmann BC, Rela M, Heaton ND, O'Grady JG, Heneghan M
Liver Transpl 2007: 13: 1382-8.

Kelly A, **Agarwal K**
Hepatitis C
Geriatric Medicine 2008 in press